Fexapotide (trifluoroacetate) is a peptide.1 It induces apoptosis in LNCaP prostate cancer cells when used at a concentration of 2.5 mg/ml. Intraprostatic administration of fexapotide triflutate (0.6 mg/animal per week) reduces the numbers of prostate glandular epithelial cells without affecting other cell types and decreases prostate volume in rats.
References:
[1].Averback, P., Gohal, R., Fuska, M., et al.Fexapotide triflutate induces selective prostate glandular pharmaco-ablation in the ratRes. Rep. Urol.11343-350(2019).
















